Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) rose 14% on Monday after an insider bought additional shares in the company. The stock traded as high as $27.86 and last traded at $27.48, with a volume of 678,318 shares traded. The stock had previously closed at $24.10.
Specifically, CEO Rick E. Winningham acquired 10,000 shares of the stock in a transaction dated Friday, August 11th. The stock was purchased at an average price of $24.50 per share, with a total value of $245,000.00. Following the transaction, the chief executive officer now directly owns 866,377 shares of the company’s stock, valued at $21,226,236.50. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Henrietta Fore acquired 6,000 shares of the stock in a transaction dated Friday, August 11th. The stock was acquired at an average cost of $23.99 per share, with a total value of $143,940.00. Following the transaction, the director now directly owns 24,000 shares in the company, valued at $575,760. The disclosure for this purchase can be found here. 6.10% of the stock is currently owned by company insiders.
TBPH has been the subject of a number of recent analyst reports. Leerink Swann set a $47.00 price objective on Theravance Biopharma and gave the stock a “buy” rating in a research report on Wednesday, May 10th. Needham & Company LLC raised their price objective on Theravance Biopharma from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, May 11th. BidaskClub raised Theravance Biopharma from a “hold” rating to a “buy” rating in a research report on Saturday, June 24th. Cantor Fitzgerald set a $55.00 price objective on Theravance Biopharma and gave the stock a “buy” rating in a research report on Wednesday, July 19th. Finally, ValuEngine raised Theravance Biopharma from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Four research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $41.13.
The firm has a 50 day moving average price of $35.84 and a 200-day moving average price of $35.42. The firm’s market capitalization is $1.48 billion.
Institutional investors have recently modified their holdings of the company. QS Investors LLC bought a new position in Theravance Biopharma during the second quarter valued at about $100,000. Ameritas Investment Partners Inc. increased its stake in shares of Theravance Biopharma by 1,494.3% in the first quarter. Ameritas Investment Partners Inc. now owns 3,635 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 3,407 shares during the period. Aperio Group LLC acquired a new stake in shares of Theravance Biopharma during the second quarter valued at $205,000. BNP Paribas Arbitrage SA increased its stake in shares of Theravance Biopharma by 570.7% in the second quarter. BNP Paribas Arbitrage SA now owns 5,151 shares of the biopharmaceutical company’s stock valued at $205,000 after buying an additional 4,383 shares during the period. Finally, Amalgamated Bank acquired a new stake in shares of Theravance Biopharma during the second quarter valued at $214,000. Hedge funds and other institutional investors own 82.77% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://stocknewstimes.com/2017/08/14/theravance-biopharma-inc-nasdaqtbph-stock-price-up-14-after-insider-buying-activity.html.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
